What is the recommended work‑up and treatment approach for cervical cancer?

Recommended Work-up and Treatment for Cervical Cancer

For early-stage cervical cancer (IA1-IIA1), radical hysterectomy with bilateral pelvic lymph node dissection (with or without sentinel lymph node mapping) is the standard treatment, while locally advanced disease (IB2-IVA) requires concurrent chemoradiotherapy with weekly cisplatin 40 mg/m² followed by brachytherapy, and metastatic/recurrent disease should be treated with paclitaxel, cisplatin, and bevacizumab as first-line therapy 1, 2.

Initial Work-up

The diagnostic evaluation must include:

• Clinical examination: Complete pelvic-rectal examination to assess tumor size, parametrial involvement, and vaginal extension
• Imaging: CT or PET/CT scan to evaluate lymph node status and rule out distant metastasis 1
• Pathology: Histologic confirmation with assessment of lymphovascular space invasion (LVSI), which significantly impacts treatment decisions
• Staging: Use both FIGO and TNM classifications to guide treatment algorithms 3

Treatment by Stage

Stage IA1 (Microscopic Disease)

• Without LVSI: Conization with negative margins is curative 1
• With LVSI: Add pelvic lymph node dissection or sentinel lymph node biopsy due to increased risk of nodal involvement 1
• Fertility preservation: Cone biopsy alone if margins negative and no LVSI 1

Stage IA2

• Standard treatment: Radical hysterectomy with bilateral pelvic lymph node dissection 1
• Fertility preservation: Radical trachelectomy with pelvic lymph node dissection 1

Stage IB1-IIA1 (Early-Stage)

• Primary surgery: Radical hysterectomy (type C) with bilateral pelvic lymph node dissection, incorporating sentinel lymph node mapping when feasible 1, 2
• Critical caveat: Surgery should ONLY be performed if no risk factors requiring adjuvant therapy are anticipated, as multimodal therapy increases toxicity without survival benefit 1
• Fertility preservation for tumors <2 cm: Radical trachelectomy with pelvic lymphadenectomy 1
• Fertility preservation for tumors >2 cm: Consider neoadjuvant chemotherapy followed by conization or trachelectomy 1

Sentinel lymph node mapping: Detection must occur bilaterally with sensitivity of 89-90% 2. This approach reduces the need for complete pelvic lymphadenectomy in appropriate candidates.

Stage IB2-IIA2 (Bulky Early-Stage)

• Primary treatment: Pelvic external beam radiotherapy (EBRT) + concurrent platinum-containing chemotherapy + brachytherapy 2
• Alternative abroad: Neoadjuvant chemotherapy followed by radical hysterectomy may be considered, though chemoradiotherapy is preferred in the United States 2

Stage IIB-IVA (Locally Advanced)

• Standard of care: Concurrent chemoradiotherapy with weekly cisplatin 40 mg/m² during EBRT, followed by brachytherapy 1
  • This regimen has demonstrated improvement in both disease-free survival and overall survival for nearly two decades 1
  • Non-platinum agents also show benefit but cisplatin remains standard 1
• Para-aortic lymph node positive: Extended-field EBRT + concurrent platinum-containing chemotherapy ± brachytherapy 2

Adjuvant Treatment After Surgery

Risk stratification determines adjuvant therapy:

• Intermediate-risk factors: No further adjuvant therapy needed 1
• High-risk factors (positive margins, parametrial involvement, positive lymph nodes): Adjuvant chemoradiotherapy is mandatory 1

Critical pitfall: Avoid surgery in patients likely to require adjuvant radiotherapy, as combined modality treatment increases toxicity without survival benefit 1.

Metastatic/Recurrent Disease

First-Line Systemic Therapy

Paclitaxel + cisplatin + bevacizumab is the preferred regimen based on superior efficacy-toxicity balance 1. This combination has demonstrated superiority over cisplatin-based doublets alone.

• Alternative for cisplatin-intolerant patients: Paclitaxel + carboplatin (without bevacizumab) 1
• Performance status requirement: PS <2 with no formal contraindications 1
• Goal: Symptom relief and quality of life improvement 1

Centrally Confined Recurrence

• Pelvic exenteration: Potentially curative for recurrent disease confined to central pelvis without distant metastasis 2

Follow-up Schedule

• Years 1-2: Every 3-6 months with complete physical and pelvic-rectal examination 1
• Years 3-5: Every 6-12 months 1
• After 5 years: Annual population-based examinations 1
• Imaging: CT or PET/CT as clinically indicated, not routine 1

All follow-up should be conducted by physicians experienced in cancer surveillance 1.

Key Clinical Pitfalls to Avoid

1. Do not perform radical surgery on patients with risk factors requiring adjuvant therapy - this creates unnecessary toxicity without survival benefit 1
2. Ensure bilateral sentinel lymph node detection - unilateral detection is inadequate 1
3. Do not use simple hysterectomy for IA2-IIA1 disease - radical approach with wider margins is required 2
4. Always add concurrent chemotherapy to radiotherapy for locally advanced disease - radiotherapy alone is inferior 1